These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application.
    Author: Yeh HH, Yang YH, Chen SH.
    Journal: Electrophoresis; 2010 Jun; 31(11):1903-11. PubMed ID: 20446294.
    Abstract:
    A nonionic surfactant MEKC method with LIF detection was developed for the simultaneous determination of memantine, an anti-Alzheimer's disease agent, and amantadine, an anti-Parkinson's disease drug, in human plasma. Before analysis, the plasma samples were pretreated by liquid-liquid extraction with ethyl acetate, and derivatized with 6-carboxyfluorescein N-hydroxysuccinimide ester. The chemical derivatization is performed with 6-carboxyfluorescein N-hydroxysuccinimide ester in ACN - 5 mM pH 9.0 borate buffer (40:60, v/v) at 35 degrees C for 3 h. After the derivatization reaction, hydrodynamic injection (0.5 psi, 8 s) was used to introduce the derivatized solution, and the separation was performed in borate buffer (30 mM, pH 9.5) with the nonionic surfactant Brij-35 (0.07%, w/v); the separation voltage was 6 kV. The linear ranges of the method for the determination of memantine and amantadine in human plasma were over a range of 2.0-60.0 ng/mL. The detection limit was 0.5 ng/mL (S/N=3). This method was applied successfully to monitor the concentration of memantine or amantadine in patients with Alzheimer's disease or Parkinson's disease.
    [Abstract] [Full Text] [Related] [New Search]